Edwards Stays On Track For ‘Mid-Teens’ TAVR Growth In 2021
Edwards Lifesciences reported $1.2bn in sales in the first quarter of 2021, up 5% year-over-year and exceeding the projections the company offered three months ago.
You may also be interested in...
J.P. Morgan Highlights: Medtech Company Updates For 2022
The annual J.P. Morgan Healthcare Conference saw major medtech companies describe their experiences in 2021 and expectations for 2022 as they continue to cope with COVID-19.
JPM 2022: Dexcom, Edwards, J&J, Medtronic, ResMed
The annual J.P. Morgan Healthcare Conference includes presentations from major medtech companies describing their experience in 2021 and expectations for 2022 as they continue to cope with the impact of the Omicron surge. Here are some of the highlights from the presentations on the first day of the meeting.
FDA Approves Edwards’ Sapien 3 With The Alterra Prestent For Pulmonary Regurgitation
The new device combines Edwards’ market-leading Sapien 3 transcatheter heart valve with its Alterra adaptive prestent device to treat patients with severe pulmonary regurgitation due to congenital valve defects.